To the best of our knowledge, osimertinib has been administered as a first‐line targeted therapy to five patients with untreated EGFR‐mutated squamous cell lung carcinoma (Table 1) [10, 11, 12, 13]. The gene discussed is EGFR; the disease is squamous cell lung carcinoma.